GBI finished manufacturing the active mAb for the ovarian cancer vaccine.
Goodwin Biotechnology (GBI) has completed the manufacture of the mAb Abagovomab, which is the active principle of Menarini Group’s Phase III ovarian cancer vaccine.
The mAb, produced to standards fully compliant with U.S. and European requirements, will be used to kick off the initial phase of a multicenter clinical trial known as MIMOSA (Monoclonal antibody Immunotherapy for Malignancies of the Ovary by Subcutaneous Abagovomab). Abagovomab will be administered as a maintenance therapy after surgery and first-line platinum plus taxane chemotherapy with the aim to prevent the reappearance of tumor and prolong survival. Around 900 women will be enrolled, according to Menarini.